Haoru Wang1, Xin Chen1, Jin Zhu2, Ke Zhang1, Jiandong Lu3, Li Zhang1, Hao Ding1, Ling He4. 1. Department of Radiology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, No. 136 Zhongshan Road 2, Yuzhong District, Chongqing, 400014, China. 2. Department of Pathology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, No. 136 Zhongshan Road 2, Yuzhong District, Chongqing, 400014, China. 3. Department of Urology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, No. 136 Zhongshan Road 2, Yuzhong District, Chongqing, 400014, China. 4. Department of Radiology, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, No. 136 Zhongshan Road 2, Yuzhong District, Chongqing, 400014, China. doctorheling@yeah.net.
Abstract
PURPOSE: To observe the changes in image-defined risk factors (IDRFs) with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma and to investigate the correlations between IDRF changes and histopathological features. In addition, this study also investigated the correlations between residual IDRFs after neoadjuvant chemotherapy and intraoperative complications. METHODS: Forty-three patients with abdominal neuroblastoma who received neoadjuvant chemotherapy in our hospital from January 2015 to September 2021 were enrolled. Intraoperative records, histopathological features, and CT images at initial diagnosis and after neoadjuvant chemotherapy of all patients were retrospectively collected and analyzed. RESULTS: A total of 245 IDRFs were found at initial diagnosis, with a median of 6 [5, 7] IDRFs per patient. After neoadjuvant chemotherapy, IDRFs significantly decreased to 156 (p < 0.001), with a median of 4 [3, 5] IDRFs remaining per patient. The majority of IDRFs (6/8, 75.00%) were significantly improved after neoadjuvant chemotherapy (p < 0.05), while tumor invasion of renal pedicles (p > 0.05) and adjacent structures (p > 0.05) was the least responsive IDRF. IDRFs in different types of neuroblastoma decreased significantly after neoadjuvant chemotherapy (p < 0.05), while they were not significant in neuroblastoma with low and intermediate mitosis-karyorrhexis indices (p > 0.05). The number of residual IDRFs correlated positively with the volumes of intraoperative blood loss (r = 0.399, p = 0.008), but not with the presence of intraoperative complications (r = 0.111, p = 0.478). CONCLUSIONS: IDRFs in different types of neuroblastoma can be significantly improved after neoadjuvant chemotherapy, while IDRFs in neuroblastoma with low and intermediate mitosis-karyorrhexis indices might not be easily improved. At the same time, the number of residual IDRFs after neoadjuvant chemotherapy might not correlate with the occurrence of intraoperative complications in abdominal neuroblastoma.
PURPOSE: To observe the changes in image-defined risk factors (IDRFs) with neoadjuvant chemotherapy in pediatric abdominal neuroblastoma and to investigate the correlations between IDRF changes and histopathological features. In addition, this study also investigated the correlations between residual IDRFs after neoadjuvant chemotherapy and intraoperative complications. METHODS: Forty-three patients with abdominal neuroblastoma who received neoadjuvant chemotherapy in our hospital from January 2015 to September 2021 were enrolled. Intraoperative records, histopathological features, and CT images at initial diagnosis and after neoadjuvant chemotherapy of all patients were retrospectively collected and analyzed. RESULTS: A total of 245 IDRFs were found at initial diagnosis, with a median of 6 [5, 7] IDRFs per patient. After neoadjuvant chemotherapy, IDRFs significantly decreased to 156 (p < 0.001), with a median of 4 [3, 5] IDRFs remaining per patient. The majority of IDRFs (6/8, 75.00%) were significantly improved after neoadjuvant chemotherapy (p < 0.05), while tumor invasion of renal pedicles (p > 0.05) and adjacent structures (p > 0.05) was the least responsive IDRF. IDRFs in different types of neuroblastoma decreased significantly after neoadjuvant chemotherapy (p < 0.05), while they were not significant in neuroblastoma with low and intermediate mitosis-karyorrhexis indices (p > 0.05). The number of residual IDRFs correlated positively with the volumes of intraoperative blood loss (r = 0.399, p = 0.008), but not with the presence of intraoperative complications (r = 0.111, p = 0.478). CONCLUSIONS: IDRFs in different types of neuroblastoma can be significantly improved after neoadjuvant chemotherapy, while IDRFs in neuroblastoma with low and intermediate mitosis-karyorrhexis indices might not be easily improved. At the same time, the number of residual IDRFs after neoadjuvant chemotherapy might not correlate with the occurrence of intraoperative complications in abdominal neuroblastoma.
Authors: Daniel A Morgenstern; Rochelle Bagatell; Susan L Cohn; Michael D Hogarty; John M Maris; Lucas Moreno; Julie R Park; Andrew D Pearson; Gudrun Schleiermacher; Dominique Valteau-Couanet; Wendy B London; Meredith S Irwin Journal: Pediatr Blood Cancer Date: 2018-11-26 Impact factor: 3.167
Authors: Anne L Ryan; Adesola Akinkuotu; Agostino Pierro; Daniel A Morgenstern; Meredith S Irwin Journal: J Pediatr Hematol Oncol Date: 2020-01 Impact factor: 1.289
Authors: Lucas Moreno; Dongjing Guo; Meredith S Irwin; Frank Berthold; Michael Hogarty; Takehiko Kamijo; Daniel Morgenstern; Claudia Pasqualini; Shifra Ash; Ulrike Potschger; Ruth Ladenstein; Dominique Valteau-Couanet; Susan L Cohn; Andrew D J Pearson; Wendy B London Journal: Pediatr Blood Cancer Date: 2020-11-18 Impact factor: 3.167
Authors: Tom Monclair; Garrett M Brodeur; Peter F Ambros; Hervé J Brisse; Giovanni Cecchetto; Keith Holmes; Michio Kaneko; Wendy B London; Katherine K Matthay; Jed G Nuchtern; Dietrich von Schweinitz; Thorsten Simon; Susan L Cohn; Andrew D J Pearson Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Janina Fischer; Alexandra Pohl; Ruth Volland; Barbara Hero; Martin Dübbers; Grigore Cernaianu; Frank Berthold; Dietrich von Schweinitz; Thorsten Simon Journal: BMC Cancer Date: 2017-08-04 Impact factor: 4.430
Authors: Sara A Mansfield; M Beth McCarville; John T Lucas; Matthew J Krasin; Sara M Federico; Victor M Santana; Wayne L Furman; Andrew M Davidoff Journal: Ann Surg Oncol Date: 2021-07-02 Impact factor: 5.344
Authors: Yesenia Rojas; Sergio Jaramillo; Karen Lyons; Nadia Mahmood; Meng-Fen Wu; Hao Liu; Sanjeev A Vasudevan; R Paul Guillerman; Chrystal U Louis; Heidi V Russell; Jed G Nuchtern; Eugene S Kim Journal: J Pediatr Surg Date: 2016-06-07 Impact factor: 2.549